Skip to content

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems.

The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks).

During the study, participants will visit their study clinic several times.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 to 75

Participation Criteria

Inclusion Criteria:

1. Male or female aged 18-75 years old with diagnosis of UC for at least 30 days. In South Korea, the age requirement for adult participants is ≥19 years of age.
2. Confirmed diagnosis of moderately to severely active UC assessed by mMS and ES.
3. Participants with a history of inadequate response to, loss of response to, or intolerance to one or more of conventional, biologic or advance therapies for UC.
4. Participants must meet the contraception recommendations.

Exclusion Criteria:

1. Participants with indeterminate/unclassified inflammatory bowel disease (IBD), microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, diverticular disease associated with colitis, and/or clinical/histologic findings suggestive of Crohn's disease (CD).
2. Participants with complications of UC such as strictures, stenoses, fistulas, short gut syndrome, or any other manifestation that might require surgery during the study.
3. Participants with a current ileostomy or colostomy. Participants who had a J-pouch are excluded, as a J-pouch could result in a stoma.
4. Participants who have failed 3 or more classes of advanced therapies.

Study Location

London Health Sciences Centre - University Hospital
London Health Sciences Centre - University Hospital
London, Ontario
Canada

Contact Study Team

Primary Contact

Site Contact

[email protected]
8442762530
Fraser Clinical Trials
Fraser Clinical Trials
New Westminster, British Columbia
Canada

Contact Study Team

Primary Contact

Site Contact

6045250155
The Research Institute of the McGill University Health Center
The Research Institute of the McGill University Health Center
Montreal, Quebec
Canada

Contact Study Team

Primary Contact

Site Contact

[email protected]
(514) 934-8309
London Health Sciences Centre - Victoria Hospital
London Health Sciences Centre - Victoria Hospital
London, Ontario
Canada

Contact Study Team

Primary Contact

Site Contact

[email protected]
5196676878
Heritage Medical Research Clinic - University Of Calgary
Heritage Medical Research Clinic - University Of Calgary
Calgary, Alberta
Canada

Contact Study Team

Primary Contact

Site Contact

[email protected]
(403) 592-5013
Centre Hospitalier de l'Universite de Montreal
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec
Canada

Contact Study Team

Primary Contact

Site Contact

[email protected]
5142953671
Study Sponsored By
Takeda
Participants Required
More Information
Study ID: NCT06254950